EP0164754B1 - Process for producing n-acetylneuraminate lyase - Google Patents

Process for producing n-acetylneuraminate lyase Download PDF

Info

Publication number
EP0164754B1
EP0164754B1 EP85107297A EP85107297A EP0164754B1 EP 0164754 B1 EP0164754 B1 EP 0164754B1 EP 85107297 A EP85107297 A EP 85107297A EP 85107297 A EP85107297 A EP 85107297A EP 0164754 B1 EP0164754 B1 EP 0164754B1
Authority
EP
European Patent Office
Prior art keywords
lyase
dna
hybrid vector
acetylneuraminate
hindiii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP85107297A
Other languages
German (de)
French (fr)
Other versions
EP0164754A1 (en
Inventor
Takayuki Uwajima
Kazuo Aisaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of EP0164754A1 publication Critical patent/EP0164754A1/en
Application granted granted Critical
Publication of EP0164754B1 publication Critical patent/EP0164754B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/848Escherichia
    • Y10S435/849Escherichia coli

Definitions

  • the present invention relates to a process for producing N-acetylneuraminate lyase (hereinafter referred to as "NA lyase”) using a microorganism constructed by recombinant DNA techniques.
  • NA lyase N-acetylneuraminate lyase
  • NA lyase (EC 4.1.3.3) is the enzyme which catalyzes the conversion reaction of N-acetylneuraminate into N-acetyl-D-mannosamine and pyruvate.
  • the enzyme is used for the determination of a substance containing sialic acid in serum for diagnostic purposes. It is also known that the enzyme exists in animal tissue, pathogenic microorganisms such as Clostridium perfringens, Vibrio cholerae, etc. and various nonpathogenic microorganisms. Only a little amount of the enzyme is produced by culturing these microorganisms in a medium which is usually used in an enzyme production.
  • N-acetylneuraminate is economically disadvantageous and it is demanded to develop the process for producing NA lyase without utilization of N-acetylneuraminate.
  • an NA lyase producing microorganism constructed by incorporating a hybrid plasmid into a recipient of the genus Escherichia produces NA lyase in a high yield in a medium which does not contain N-acetylneuraminate.
  • NA lyase is produced by culturing a microorganism belonging to the genus Escherichia and having an ability to produce NA lyase and which is obtained by incorporating into a host strain of the genus Escherichia a hybrid plasmid wherein a DNA fragment with genetic information controlling NA lyase production which is derived from a donor strain is inserted.
  • any microorganism may be used so long as it belongs to the genus Escherichia and possesses genetic information controlling NA lyase production. Strains having a higher productivity of NA lyase are preferably used as the DNA-donor.
  • chromosomal DNA The DNA with genetic information controlling NA lyase production (hereinafter referred to as "chromosomal DNA”) is extracted from the DNA donor in a well known manner, for example, phenol method described in Biochim. Biophys. Acta, Vol. 72, pp 619 - 629 (1963).
  • the thus obtained DNA is inserted into a vector DNA to prepare a hybrid DNA.
  • the insertion of a chromosomal DNA into the vector DNA can be attained according to the usual manner.
  • the chromosomal DNA and the vector DNA is treated with a restriction endonuclease to prepare a chromosomal DNA fragment and a cleaved vector DNA and the mixture is treated with DNA ligase to obtain the hybrid DNA.
  • vector DNA a conventional vector such as pBR322, Co1E1, pSC101, pACYC177, pCR1, R6K or ⁇ -phage, or their derivatives can be employed.
  • Plasmid pBR322 is preferably used.
  • DNA ligase DNA ligase derived from T4 phage may be preferably employed.
  • the hybrid DNA thus obtained can be incorporated into a microorganism of the genus Escherichia having no ability to produce NA lyase (hereinafter referred to as "NA lyase-non-producing strain") by conventional transformation techniques such as calcium ion treatment method described in J. Bacteriol., Vol. 119, pp 1072-1074 (1974).
  • the NA lyase-non-producing strain can be obtained by the following method.
  • a wild strain of the genus Escherichia such as Escherichia coli C600-SF8 is subjected to mutation treatment to obtain a mutant having no ability to utilize N-acetylneuraminate.
  • the mutation is carried out by a conventional method, for example, treatment with mutagens such as N-methyl-N'-nitro-N-nitrosoguanidine.
  • the mutant having no ability to utilize N-acetylneuraminate can be obtained by culturing the microbial cells obtained by mutation treatment in a glucose minimal medium comprising 2 g/l glucose, 1 g/l (NH4)2SO4, 7 g/l K2HPO4, 3 g/l KH2PO4, 0.1 g/l MgSO4 ⁇ 7H2O, 5 mg/l thiamine, 0.2 mM threonine, 0.2 mM leucine and 15 g/l agar.
  • a glucose minimal medium comprising 2 g/l glucose, 1 g/l (NH4)2SO4, 7 g/l K2HPO4, 3 g/l KH2PO4, 0.1 g/l MgSO4 ⁇ 7H2O, 5 mg/l thiamine, 0.2 mM threonine, 0.2 mM leucine and 15 g/l agar.
  • the formed colonies are replicated in the glucose minimal medium and N-acetylneuraminate minimal medium comprising 2 g/l N-acetylneuraminate, 1 g/l (NH4)2SO4 7 g/l K2HPO4 3 g/l KH2PO4, 0.1 g/l MgSO4 ⁇ 7H2O, 5 mg/l thiamine, 0.2 mM threonine, 0.2 mM leucine and 15 g/l agar.
  • the colonies which can grow on the glucose minimal medium and cannot grow on the N-acetylneuraminate minimal medium are picked up to obtain NA lyase-non-producing strain.
  • An example of such strain is Escherichia coli 0-2.
  • the screening method of the desired transformant is selected according to the kind of the restriction endonuclease used for preparing the hybrid DNA or the kind of the vector DNA utilized.
  • the desired transformant is obtained by culturing the strain in the N-acetylneuraminate minimal medium containing ampicillin and picking up the formed colonies having NA lyase activity.
  • An example of the microorganism containing the hybrid DNA is Escherichia coli H3-4 FERM BP-5l3.
  • the strain was deposited on March 24, 1984 with the Fermentation Research Institute, Agency of Industrial Science and Technology located at 1-3, Higashi 1 chome, Yatabe-machi, Tsukuba-gun, Ibaraki-ken 305, JAPAN under the Budapest Treaty.
  • the method for culturing the NA lyase producing strains thus obtained is conventional, and is similar to the known method for producing enzymes.
  • a synthetic or natural medium may be used so long as it contains an appropriate carbon source, nitrogen source and inorganic materials.
  • carbohydrates such as glucose, sucrose, fructose, starch, starch hydrolyzate, molasses, etc. may be used in a concentration of 5-50 g/l.
  • organic and inorganic ammonium salts such as ammonium sulfate, ammonium phosphate, ammonium carbonate, ammonium acetate, etc., nitrogen containing organic substances such as peptone, yeast extract, corn steep liquor and casein hydrolyzate, etc. may be used in a concentration of 5 - 20 g/l.
  • potassium monohydrogen phosphate potassium dihydrogen phosphate, magnesium sulfate, manganese sulfate, etc. may be used in a concentration of 0.05-5 g/l.
  • Culturing is carried out under aerobic conditions, for example, with shaking or stirring at a temperature of 25 - 37°C for 16 - 48 hours.
  • the culture liquor is subjected to filtration, decantation, centrifugation, etc. to obtain microbial cells.
  • the microbial cells are disrupted by appropriate means such as ultrasonic disintegration, grinding, etc. to obtain a cell extract and the extract is subjected to centrifugation to obtain a supernatant. Then the supernatant is subjected to conventional purification methods such as salting-out, dialysis, chromatography using ion exchange cellulose, Sephadex, gel filtration and the like to obtain the purified enzyme.
  • the transformant strain H3 - 4 produced NA lyase using a medium which does not contain N-acetylneuraminate.
  • H3 - 4 strain was inoculated in 300 ml of the medium (pH 7.0) comprising 1 g/l glucose, 10 g/l trypton, 5 g/l yeast extract, 5 g/l sodium chloride and 20 ⁇ g/ml ampicillin in a 2 l-Erlenmeyer flask and cultured at 30°C with shaking for 18 hours.
  • the culture liquor was subjected to centrifugation to obtain microbial cells.
  • the microbial cells were suspended in 20 ml of 0.01M phosphate buffer (pH 7.0) and the suspension was subjected to ultrasonic disintegration to disrupt the cells and extract the enzyme.
  • the precipitates were dissolved in 5 ml of 0.01M phosphate buffer (pH 7.0) and the solution was subjected to dialysis with 1 l of the same buffer solution for 24 hours.
  • the dialysate was passed through a column (Volume: 250 ml, Diameter: 2.5 cm) packed with DEAE-Sephadex equilibrated with the same buffer solution, whereby NA lyase was adsorbed on the DEAE-Sephadex.
  • the column was washed with the same phosphate buffer to remove contaminant proteins. Concentration gradient elution was carried out with the same phosphate buffer (pH 7.0) and the same phosphate buffer containing 1.0M NaCl.
  • the active fractions were combined and the precipitates which were deposited by the addition of ammonium sulphate up to a saturation of 90% were recovered by centrifugation (12,000 xg, 20 minutes) and were dissolved in 5 ml of 0.01M phosphate buffer (pH 7.0).
  • the solution was subjected to dialysis with 1 l of the same buffer (pH 7.0) for 24 hours.
  • the dialysate was subjected to freeze-drying to obtain 20 mg of purified NA lyase powder preparation (specific activity 3.0 units/mg).

Description

  • The present invention relates to a process for producing N-acetylneuraminate lyase (hereinafter referred to as "NA lyase") using a microorganism constructed by recombinant DNA techniques.
  • NA lyase (EC 4.1.3.3) is the enzyme which catalyzes the conversion reaction of N-acetylneuraminate into N-acetyl-D-mannosamine and pyruvate.
  • It is known that the enzyme is used for the determination of a substance containing sialic acid in serum for diagnostic purposes. It is also known that the enzyme exists in animal tissue, pathogenic microorganisms such as Clostridium perfringens, Vibrio cholerae,etc. and various nonpathogenic microorganisms. Only a little amount of the enzyme is produced by culturing these microorganisms in a medium which is usually used in an enzyme production.
  • It has been reported that the yield of the enzyme was enhanced by adding N-acetylneuraminate to the medium (Japanese Patent Publication Nos. 54153/81 and 51751/81).
  • The utilization of N-acetylneuraminate is economically disadvantageous and it is demanded to develop the process for producing NA lyase without utilization of N-acetylneuraminate.
  • As a result of studies made to develop such a process, it has been found that an NA lyase producing microorganism constructed by incorporating a hybrid plasmid into a recipient of the genus Escherichia produces NA lyase in a high yield in a medium which does not contain N-acetylneuraminate.
  • In accordance with the present invention, NA lyase is produced by culturing a microorganism belonging to the genus Escherichia and having an ability to produce NA lyase and which is obtained by incorporating into a host strain of the genus Escherichia a hybrid plasmid wherein a DNA fragment with genetic information controlling NA lyase production which is derived from a donor strain is inserted.
  • As the DNA-donor strain used to construct the NA lyase producer of the present invention, any microorganism may be used so long as it belongs to the genus Escherichia and possesses genetic information controlling NA lyase production. Strains having a higher productivity of NA lyase are preferably used as the DNA-donor.
  • The DNA with genetic information controlling NA lyase production (hereinafter referred to as "chromosomal DNA") is extracted from the DNA donor in a well known manner, for example, phenol method described in Biochim. Biophys. Acta, Vol. 72, pp 619 - 629 (1963).
  • The thus obtained DNA is inserted into a vector DNA to prepare a hybrid DNA. The insertion of a chromosomal DNA into the vector DNA can be attained according to the usual manner.
  • The chromosomal DNA and the vector DNA is treated with a restriction endonuclease to prepare a chromosomal DNA fragment and a cleaved vector DNA and the mixture is treated with DNA ligase to obtain the hybrid DNA.
  • As the vector DNA, a conventional vector such as pBR322, Co1E1, pSC101, pACYC177, pCR1, R6K or λ-phage, or their derivatives can be employed. Plasmid pBR322 is preferably used.
  • Examples of the restriction endonuclease are HindIII, BamHI, EcoRI, PstI and SalI, among which HindIII is preferable. As the DNA ligase, DNA ligase derived from T4 phage may be preferably employed.
  • The hybrid DNA thus obtained can be incorporated into a microorganism of the genus Escherichia having no ability to produce NA lyase (hereinafter referred to as "NA lyase-non-producing strain") by conventional transformation techniques such as calcium ion treatment method described in J. Bacteriol., Vol. 119, pp 1072-1074 (1974).
  • The NA lyase-non-producing strain can be obtained by the following method. A wild strain of the genus Escherichia such as Escherichia coli C600-SF8 is subjected to mutation treatment to obtain a mutant having no ability to utilize N-acetylneuraminate. The mutation is carried out by a conventional method, for example, treatment with mutagens such as N-methyl-N'-nitro-N-nitrosoguanidine.
  • The mutant having no ability to utilize N-acetylneuraminate can be obtained by culturing the microbial cells obtained by mutation treatment in a glucose minimal medium comprising 2 g/l glucose, 1 g/l (NH₄)₂SO₄, 7 g/l K₂HPO₄, 3 g/l KH₂PO₄, 0.1 g/l MgSO₄·7H₂O, 5 mg/l thiamine, 0.2 mM threonine, 0.2 mM leucine and 15 g/l agar. The formed colonies are replicated in the glucose minimal medium and N-acetylneuraminate minimal medium comprising 2 g/l N-acetylneuraminate, 1 g/l (NH₄)₂SO₄ 7 g/l K₂HPO₄ 3 g/l KH₂PO₄, 0.1 g/l MgSO₄·7H₂O, 5 mg/l thiamine, 0.2 mM threonine, 0.2 mM leucine and 15 g/l agar. The colonies which can grow on the glucose minimal medium and cannot grow on the N-acetylneuraminate minimal medium are picked up to obtain NA lyase-non-producing strain. An example of such strain is Escherichia coli 0-2.
  • The screening method of the desired transformant is selected according to the kind of the restriction endonuclease used for preparing the hybrid DNA or the kind of the vector DNA utilized. When HindIII and plasmid pBR322 are used, the desired transformant is obtained by culturing the strain in the N-acetylneuraminate minimal medium containing ampicillin and picking up the formed colonies having NA lyase activity. An example of the microorganism containing the hybrid DNA is Escherichia coli H3-4 FERM BP-5l3.
  • The strain was deposited on March 24, 1984 with the Fermentation Research Institute, Agency of Industrial Science and Technology located at 1-3, Higashi 1 chome, Yatabe-machi, Tsukuba-gun, Ibaraki-ken 305, JAPAN under the Budapest Treaty.
  • The method for culturing the NA lyase producing strains thus obtained is conventional, and is similar to the known method for producing enzymes.
  • As the medium, either a synthetic or natural medium may be used so long as it contains an appropriate carbon source, nitrogen source and inorganic materials.
  • As the carbon source, carbohydrates such as glucose, sucrose, fructose, starch, starch hydrolyzate, molasses, etc. may be used in a concentration of 5-50 g/l.
  • As the nitrogen source, organic and inorganic ammonium salts such as ammonium sulfate, ammonium phosphate, ammonium carbonate, ammonium acetate, etc., nitrogen containing organic substances such as peptone, yeast extract, corn steep liquor and casein hydrolyzate, etc. may be used in a concentration of 5 - 20 g/l.
  • As the inorganic materials, potassium monohydrogen phosphate, potassium dihydrogen phosphate, magnesium sulfate, manganese sulfate, etc. may be used in a concentration of 0.05-5 g/l.
  • Culturing is carried out under aerobic conditions, for example, with shaking or stirring at a temperature of 25 - 37°C for 16 - 48 hours.
  • After completion of the culturing, the culture liquor is subjected to filtration, decantation, centrifugation, etc. to obtain microbial cells. The microbial cells are disrupted by appropriate means such as ultrasonic disintegration, grinding, etc. to obtain a cell extract and the extract is subjected to centrifugation to obtain a supernatant. Then the supernatant is subjected to conventional purification methods such as salting-out, dialysis, chromatography using ion exchange cellulose, Sephadex, gel filtration and the like to obtain the purified enzyme.
  • Certain specific embodiments of the invention are illustrated by the following representative examples.
  • Example 1
    • (1) Preparation of chromosomal DNA harboring genetic information controlling NA lyase production
      Escherichia coli KY 8482 was cultured in 300 ml of the medium (pH 7.2) comprising 1 g/l glucose, 10 g/l trypton, 5 g/l yeast extract and 5 g/l sodium chloride with shaking at 28°C for 16 hours to obtain microbial cells.
      The microbial cells were washed and treated with phenol by the method of Saito and Miura [Biochim. Biophys. Acta. 72, 619 - 629 (1963)], to obtain about 2 mg of a chromosomal DNA.
    • (2) Insertion of chromosomal DNA fragment into vector
      2.6 µg of the chromosomal DNA obtained in step (1) was treated with restriction endonuclease HindIII at 37°C for 2 hours to cleave the DNA chains and then heated at 65°C for 10 minutes. 2.6 µg of vector DNA, pBR322 (product of Bethesda Research Laboratories, Co.) was treated with restriction endonuclease HindIII at 37°C for 2 hours to cleave the DNA chains and then heated at 65°C for 10 minutes.
      The digested chromosomal DNA solution and cleaved vector DNA solution were mixed and subjected to the ligation reaction of DNA fragments with T4 phage DNA ligase at 4°C for 16 hours. The reaction mixture was heated at 65°C for 10 minutes to obtain a hybrid DNA solution.
    • (3) Genetic transformation with the hybrid plasmid harboring the genetic information controlling NA lyase production
      NA lyase-non-producing strain Escherichia coli0 - 2 which was derived from Escherichia coli C600 - SF8 by mutation treatment was cultured in 40 ml of L-medium at 37°C with shaking. Cells in exponential growth phase (OD₆₆₀ = about 0.40) were harvested and washed with 0.1M CaCl₂ solution. Then, the cells were suspended in 1 ml of 0.1M CaCl₂ solution.
      The DNA obtained in step (2) was added to 0.15 ml of the suspension. After incubating at 0°C for 30 minutes, the suspension was heated at 37°C for 20 minutes to incorporate the DNA into the cells. The cells were inoculated into 1.5 ml of L-medium and cultured at 37°C for 2 hours with shaking. The cultured cells were harvested and washed.
      The resultant cells were spread on an agar plate of N-acetylneuraminate minimal medium comprising 2 g/l N-acetylneuraminate, 1 g/l (NH₄)₂SO₄, 7 g/l K₂HPO₄, 3 g/l KH₂PO₄, 0.1 g/l MgSO₄·7H₂O, 5 µg/ml thiamine, 0.2 mM threonine, 0.2 mM leucine and 15 g/l agar (pH was adjusted to 7.0) and containing 20 µg/ml ampicillin. The plate was incubated at 30°C for 2 days. Colonies formed on the plate were picked up and examined for NA lyase activity to obtain H3 - 4 strain as NA lyase-producing transformant.
    Example 2
  • Strains indicated in Table 1 were inoculated in L-medium and in L-medium containing 1 g/l N-acetylneuraminate and were cultured at 30°C with shaking for 18 hours. After completion of the culturing, the culture liquor was subjected to centrifugation to obtain microbial cells which were then washed with physiological saline solution. The microbial cells were subjected to ultrasonic disintegration to obtain an extract. The NA lyase activity of the extract is shown in Table 1.
  • The transformant strain H3 - 4 produced NA lyase using a medium which does not contain N-acetylneuraminate.
    Figure imgb0001
  • Example 3
  • H3 - 4 strain was inoculated in 300 ml of the medium (pH 7.0) comprising 1 g/l glucose, 10 g/l trypton, 5 g/l yeast extract, 5 g/l sodium chloride and 20 µg/ml ampicillin in a 2 ℓ-Erlenmeyer flask and cultured at 30°C with shaking for 18 hours. The culture liquor was subjected to centrifugation to obtain microbial cells. The microbial cells were suspended in 20 ml of 0.01M phosphate buffer (pH 7.0) and the suspension was subjected to ultrasonic disintegration to disrupt the cells and extract the enzyme.
  • To the extract was added ammonium sulfate and the precipitates which were deposited by the saturation with 30 - 80% ammonium sulfate were recovered.
  • The precipitates were dissolved in 5 ml of 0.01M phosphate buffer (pH 7.0) and the solution was subjected to dialysis with 1 ℓ of the same buffer solution for 24 hours. The dialysate was passed through a column (Volume: 250 ml, Diameter: 2.5 cm) packed with DEAE-Sephadex equilibrated with the same buffer solution, whereby NA lyase was adsorbed on the DEAE-Sephadex.
  • The column was washed with the same phosphate buffer to remove contaminant proteins. Concentration gradient elution was carried out with the same phosphate buffer (pH 7.0) and the same phosphate buffer containing 1.0M NaCl.
  • The active fractions were combined and the precipitates which were deposited by the addition of ammonium sulphate up to a saturation of 90% were recovered by centrifugation (12,000 xg, 20 minutes) and were dissolved in 5 ml of 0.01M phosphate buffer (pH 7.0).
  • The solution was subjected to dialysis with 1 ℓ of the same buffer (pH 7.0) for 24 hours.
  • The dialysate was subjected to freeze-drying to obtain 20 mg of purified NA lyase powder preparation (specific activity 3.0 units/mg).

Claims (7)

  1. A hybrid vector into which a DNA fragment is inserted which contains a gene of a donor strain of the genus Escherichia encoding an N-acetylneuraminate lyase (NA-lyase) and which is obtainable by carrying out the following steps:
    (a) cleavage of the chromosomal DNA of the donor strain of the genus Escherichia with the restriction enzyme HindIII;
    (b) cleavage of the vector DNA with HindIII;
    (c) ligation of the DNA molecules obtained according to (a) and (b) in order to obtain hybrid vector molecules;
    (d) transformation of microorganisms of the genus Escherichia which are incapable of producing NA-lyase with hybrid vector molecules obtained according to (c);
    (e) selection of transformants containing a hybrid vector into which a HindIII DNA fragment is inserted which contains an NA-lyase gene of the donor strain of the genus Escherichia by cultivating the transformants in an N-acetylneuraminate medium containing ampicillin and picking up the formed colonies having NA-lyase activity; and
    (f) isolation of the hybrid vector from the transformant selected according to (e).
  2. The hybrid vector according to Claim 1 which is derived from one of the vectors Co1E1, pSC101, pBR322, pACYC177, pCR1, R6K or from the λ-phage.
  3. The hybrid vector according to Claim 1 or 2 which consists of a chromosomal HindIII DNA fragment derived from the donor strain Escherichia coli KY8482 inserted into the HindIII restriction site of pBR322 and which is contained in the transformant Escherichia coli H3-4 FERM BP-513.
  4. A host bacterium of the genus Escherichiacontaining a hybrid vector according to any one of Claims 1 to 3.
  5. The host bacterium according to Claim 4 which belongs to the species Escherichia coli.
  6. The host bacterium according to Claim 4 or 5 which is Escherichia coli H3-4 FERM BP-513.
  7. A process for producing N-acetylneuraminate lyase (NA-lyase) which comprises culturing in a medium a host bacterium according to any one of Claims 4 to 6 and recovering the NA-lyase accumulated in the culture medium.
EP85107297A 1984-06-14 1985-06-13 Process for producing n-acetylneuraminate lyase Expired - Lifetime EP0164754B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP122818/84 1984-06-14
JP59122818A JPH062061B2 (en) 1984-06-14 1984-06-14 Process for producing N-acetylneuraminic acid lyase

Publications (2)

Publication Number Publication Date
EP0164754A1 EP0164754A1 (en) 1985-12-18
EP0164754B1 true EP0164754B1 (en) 1991-03-06

Family

ID=14845393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85107297A Expired - Lifetime EP0164754B1 (en) 1984-06-14 1985-06-13 Process for producing n-acetylneuraminate lyase

Country Status (4)

Country Link
US (1) US4670389A (en)
EP (1) EP0164754B1 (en)
JP (1) JPH062061B2 (en)
DE (1) DE3581958D1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6181786A (en) * 1984-08-30 1986-04-25 Marukin Shoyu Kk Production of n-acylneuraminic acid aldolase
JPS62277A (en) * 1985-06-26 1987-01-06 Rikagaku Kenkyusho Novel plasmid, novel microorganism transformed therewith and production of useful physiologically active substance using same
JPS62278982A (en) * 1986-05-27 1987-12-03 Kyowa Hakko Kogyo Co Ltd Production of n-acetylneuraminic acid lyase
JPH03103338A (en) * 1989-09-14 1991-04-30 Sumitomo Electric Ind Ltd Surface-treatment of fluoride glass
US6156544A (en) * 1993-06-09 2000-12-05 Glaxo Group Limited Process for the preparation of N-acetylneuraminic acid
JPH08259253A (en) * 1995-03-24 1996-10-08 Sumitomo Electric Ind Ltd Optical fiber drawing method and drawing device
WO2003072783A1 (en) * 2002-02-28 2003-09-04 Kyowa Hakko Kogyo Co., Ltd. Process for producing n-acetylneuraminic acid
EP3149188A1 (en) 2014-05-27 2017-04-05 Universitetet I Tromsø - Norges Arktiske Universitet Use of a n-acetylneuraminate lyase derived from the bacterium aliivibrio salmonicida in the production of neuraminic acid and derivatives thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5550890A (en) * 1978-10-09 1980-04-14 Marukin Shoyu Kk Preparation of n-acylneuraminic acid aldolase
JPS5550891A (en) * 1978-10-09 1980-04-14 Marukin Shoyu Kk Preparation of n-acylneuraminic acid aldolase
JPS5654153A (en) * 1979-10-09 1981-05-14 Fujitsu Ltd Information system of failure congestion
IL61982A (en) * 1980-02-15 1984-01-31 Cpc International Inc Genetically engineered microorganisms for massive production of amyloytic enzymes and process for preparing same using the corresponding recombinant dnas containing amylase coding genes
US4362817A (en) * 1981-03-02 1982-12-07 The Upjohn Company Hybrid plasmid and process of making same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN, unexamined applications, section C, vol. 4, no. 85, June 18, 1980 THE PATENT OFFICE JAPANESE GOVERNMENT page 149 C-15 & JP-B4-54 153/81 *
PATENT ABSTRACTS OF JAPAN, unexamined applications, section C, vol. 4, no. 85,June 18, 1980 THE PATENT OFFICE JAPANESE GOVERNMENT page 149 C-15 & JP-B4-51 751/81 *

Also Published As

Publication number Publication date
EP0164754A1 (en) 1985-12-18
JPS611384A (en) 1986-01-07
US4670389A (en) 1987-06-02
JPH062061B2 (en) 1994-01-12
DE3581958D1 (en) 1991-04-11

Similar Documents

Publication Publication Date Title
RU1838410C (en) Method of obtaining alpha-amylase
US11225675B2 (en) D-lactate dehydrogenase, engineered strain containing D-lactate dehydrogenase and construction method and use of engineered strain
KR101083136B1 (en) Microorganisms for producing l-amino acids and process for producing l-amino acids using them
US5888786A (en) Method for producing 2-keto-L-gulonic acid
CN101463358B (en) Nitrile hydratase gene cluster and use thereof
KR970001238B1 (en) Process for l-tryptophan
EP0164754B1 (en) Process for producing n-acetylneuraminate lyase
US4806480A (en) Novel E. coli hybrid plasmid vector conferring sucrose fermenting capacity
US4464471A (en) Biologically engineered plasmid coding for production of β-glucosidase, organisms modified by this plasmid and methods of use
EP0123903B1 (en) Method for producing l-aspartic acid
US4598046A (en) Mutant strain of Escherichia coli and its use for the preparation of glutathione
EP0107400A1 (en) Hybrid plasmid and process for producing glutathione using said plasmid
EP0385415B1 (en) Process for producing NADH oxidase
EP0402929B1 (en) A dna fragment containing a gene encoding creatinine amidohydrolase
EP0312089B1 (en) Method for producing L-threonine
EP0180192B1 (en) Novel plasmids
EP0281104B1 (en) Novel plasmids
EP0146929A2 (en) Microorganism of the genus Serratia containing a hybrid plasmid and process for preparing the same
JPH0559705B2 (en)
RU2314346C2 (en) Plasmids for chromosome recombination of escherichia coli
JPS6228678B2 (en)
CN116949108A (en) L-glutamine exoprotein, mutant thereof and application thereof
KR20230065393A (en) Method for increasing productivity of 2'-fucosyllactose by changing medium composition and culture method
CN115927267A (en) Bile acid complex enzyme preparation and application thereof in preparation of feed additive for improving digestibility of animal protein
CN115612681A (en) Protein mutant, recombinant bacterium, preparation method and application thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): DE FR GB IT

17P Request for examination filed

Effective date: 19860304

17Q First examination report despatched

Effective date: 19871110

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE FR GB IT

ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

ET Fr: translation filed
REF Corresponds to:

Ref document number: 3581958

Country of ref document: DE

Date of ref document: 19910411

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20020610

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20020612

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20020619

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20030613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040227

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST